Table 2

Estimated and actual fears as well as experienced factors affecting the decision to decline long-acting injectable antipsychotics (LAIs)

FactorsMental health
professionals
    (n = 63)
Patients on oral
treatment
(n = 101)
PPatients on LAIs
(n = 63)
Pa
Pain at the injection site50.5 (11–95)28 (0–100)  0.00112 (0–100)0.21
Being regularly tied to a clinic49 (5–98)62 (0–100)  0.2428 (0–99)0.018
Observation time at the clinic after one
certain type of LAIb
64 (4–98)89 (0–100)<0.000167 (3–98)0.23
Embarrassment of having an injection41 (1–93)12 (0–98)<0.0001  7 (0–100)0.11
Reduction in autonomy62 (5–93)30 (0–98)  0.002510 (0–100)0.18
Loss of ability to decide when to take the
medication
56 (4–95)45 (0–100)  0.13  8 (0–98)0.001
Feeling of being controlled56 (3–94)25 (0–100)  0.01313 (0–100)0.58
Perceptions of stigma of being on LAI51 (4–88)17 (0–100)  0.000411 (0–100)0.63
  • The questions were presented orally and adapted based on the participant category, i.e. mental health professionals, patients on oral treatment and patients on LAIs.

  • a. Patients on oral treatment v. patients on LAIs.

  • b. Only the 7 patients on long-acting injectable olanzapine who had experienced a 3 h observation time were included.